Supernus Pharmaceuticals PE Ratio 2012-2026 | SUPN
Current and historical p/e ratio for Supernus Pharmaceuticals (SUPN) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Supernus Pharmaceuticals PE ratio as of June 05, 2026 is 22.33.
| Supernus Pharmaceuticals PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-05 | 44.75 | 0.00 | |
| 2026-03-31 | 51.69 | $-0.51 | 0.00 |
| 2025-12-31 | 49.70 | $-0.68 | 0.00 |
| 2025-09-30 | 47.79 | $-0.34 | 0.00 |
| 2025-06-30 | 31.52 | $1.15 | 27.41 |
| 2025-03-31 | 32.75 | $1.11 | 29.50 |
| 2024-12-31 | 36.16 | $1.32 | 27.39 |
| 2024-09-30 | 31.18 | $1.09 | 28.61 |
| 2024-06-30 | 26.75 | $0.11 | 243.18 |
| 2024-03-31 | 34.11 | $-0.27 | 0.00 |
| 2023-12-31 | 28.94 | $0.02 | 1447.00 |
| 2023-09-30 | 27.57 | $0.42 | 65.64 |
| 2023-06-30 | 30.06 | $0.74 | 40.62 |
| 2023-03-31 | 36.23 | $0.90 | 40.26 |
| 2022-12-31 | 35.67 | $1.04 | 34.30 |
| 2022-09-30 | 33.85 | $0.64 | 52.89 |
| 2022-06-30 | 28.92 | $1.01 | 28.63 |
| 2022-03-31 | 32.32 | $1.30 | 24.86 |
| 2021-12-31 | 29.16 | $0.98 | 29.76 |
| 2021-09-30 | 26.67 | $1.51 | 17.66 |
| 2021-06-30 | 30.79 | $1.85 | 16.64 |
| 2021-03-31 | 26.18 | $2.07 | 12.65 |
| 2020-12-31 | 25.16 | $2.36 | 10.66 |
| 2020-09-30 | 20.84 | $2.40 | 8.68 |
| 2020-06-30 | 23.75 | $2.20 | 10.80 |
| 2020-03-31 | 17.99 | $2.16 | 8.33 |
| 2019-12-31 | 23.72 | $2.10 | 11.30 |
| 2019-09-30 | 27.48 | $1.96 | 14.02 |
| 2019-06-30 | 33.09 | $1.94 | 17.06 |
| 2019-03-31 | 35.04 | $1.90 | 18.44 |
| 2018-12-31 | 33.22 | $2.05 | 16.20 |
| 2018-09-30 | 50.35 | $1.86 | 27.07 |
| 2018-06-30 | 59.85 | $1.63 | 36.72 |
| 2018-03-31 | 45.80 | $1.38 | 33.19 |
| 2017-12-31 | 39.85 | $1.08 | 36.90 |
| 2017-09-30 | 40.00 | $1.12 | 35.71 |
| 2017-06-30 | 43.10 | $2.01 | 21.44 |
| 2017-03-31 | 31.30 | $1.87 | 16.74 |
| 2016-12-31 | 25.25 | $1.76 | 14.35 |
| 2016-09-30 | 24.73 | $1.58 | 15.65 |
| 2016-06-30 | 20.37 | $0.48 | 42.44 |
| 2016-03-31 | 15.25 | $0.34 | 44.85 |
| 2015-12-31 | 13.44 | $0.28 | 48.00 |
| 2015-09-30 | 14.03 | $0.24 | 58.46 |
| 2015-06-30 | 16.98 | $0.10 | 169.80 |
| 2015-03-31 | 12.09 | $0.14 | 86.36 |
| 2014-12-31 | 8.30 | $-0.26 | 0.00 |
| 2014-09-30 | 8.69 | $-0.99 | 0.00 |
| 2014-06-30 | 10.95 | $-1.71 | 0.00 |
| 2014-03-31 | 8.94 | $-2.68 | 0.00 |
| 2013-12-31 | 7.54 | $-2.90 | 0.00 |
| 2013-09-30 | 7.33 | $2.22 | 3.30 |
| 2013-06-30 | 6.43 | $2.45 | 2.62 |
| 2013-03-31 | 5.62 | $2.73 | 2.06 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.918B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |